is disease-free survival a meaningful endpoint in nsclc? - medpage today
Published 2 years ago • 69 plays • Length 4:44Download video MP4
Download video MP3
Similar videos
-
21:02
what did we learn from impower010 in resectable nsclc? - medpage today
-
1:21
immunotherapy-chemo offers survival advantage in low pd-l1 nsclc - medpage today
-
5:10
disease-free survival: endpoint for adjuvant therapy for cancer?
-
11:09
chemo-io over io alone in patients with advanced nsclc - medpage today
-
6:05
adaura: extremely positive data in early nsclc, but questions remain - medpage today
-
6:07
no survival benefit seen with regorafenib in advanced chordoma - medpage today
-
15:32
asco roundtable: lung cancer highlights - medpage today
-
3:01
esmo: first-line erlotinib improves nsclc outcomes
-
2:17
iaslc: targeted agent slows lung ca symptoms
-
7:22
tumor 'hyperprogression' after immunotherapy - medpage today
-
3:54
could magic johnson get into an oncology trial? - medpage today
-
4:28
cdk4/6 inhibitor maintained os benefit in advanced breast cancer - medpage today
-
2:44
disease-free survival in impower010 trial: adjuvant atezolizumab in nsclc
-
3:25
is progression-free survival meaningful?
-
3:14
parp inhibitor staves off recurrence in early brca-mutant breast cancer - medpage today
-
6:29
upfront triplet therapy has os advantage in men with mcspc - medpage today
-
6:27
similar disease free survival with sublobar resection we must do more
-
4:39
keytruda 'switch' extends pfs in advanced bladder cancer - medpage today
-
2:19
checkmate 274: biomarkers linked to disease-free survival with adjuvant nivolumab